Spyre Therapeutics, Inc ((SYRE)) announced an update on their ongoing clinical study.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Spyre Therapeutics, Inc. is conducting a Phase 2 study titled ‘Phase 2 Platform Trial to Assess the Efficacy and Safety of Long-acting Antibodies as Single Agents and in Combinations for Moderately to Severely Active Ulcerative Colitis.’ The study aims to evaluate the efficacy and safety of various long-acting antibody treatments for adults with moderate to severe ulcerative colitis, a significant condition affecting many individuals worldwide.
The study is testing several experimental drugs, including SPY001, SPY002, and SPY003, alone and in combination. These drugs are designed to manage symptoms and improve the quality of life for patients with ulcerative colitis.
This interventional study is randomized with a parallel assignment model. It employs quadruple masking, meaning that the participant, care provider, investigator, and outcomes assessor are all blinded. The primary purpose of the study is treatment-focused.
The study began on May 27, 2025, with the latest update submitted on October 17, 2025. These dates are crucial as they indicate the study’s progression and current status, which is actively recruiting participants.
The outcome of this study could significantly impact Spyre Therapeutics’ stock performance, as successful results may lead to increased investor confidence and market share. The competitive landscape in the ulcerative colitis treatment market is intense, with several companies vying for breakthroughs in this area.
The study is ongoing, with further details available on the ClinicalTrials portal.